We will evaluate the overall hypothesis that the combined treatment with the vaccines that induce particular chemokine receptors (CKR) on tumor-specific effector T cells with the treatments that induce the production of the relevant chemokines selectively within tumors, will result in therapeutic synergism, by directing tumorspecific T cells to tumors. Our proposal is based on our development of a new dendritic cell variant (aDC1s) with a unique ability of to induce a defined pattern of CKRs on tumor-specific T cells (selectively-enhanced expression of CXCR3 and CCR5), and our development of several complementary strategies to selectively enhance the production of the relevant chemokines in different tumor tissues. This Program involves three Research Projects: Project 1: Tumor-Specific Chemokine Modulation in Colorectal Cancer versus Melanoma;Project 2: Type-1 Antigen Presenting Cells in the CMS Tumors: the Key to Efficient Anti-tumor Immunity;Project 3: Tumor-selective Oncolytic Vaccinia Virus and aDC1-based Vaccine as a Combination Therapy for Colorectal Cancer. Our ongoing clinical trials in melanoma, colorectal cancer, and glioma, will provide the patient material for the laboratory studies proposed in years 1-3. The paradigms and methods developed within this period will result in the clinical introduction of new combination therapies of cancer (vaccination + chemokine-targeting regimen) that will be clinically tested in years 4-5 of this Program.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Research Program Projects (P01)
Project #
Application #
Study Section
Special Emphasis Panel (ZCA1-RPRB-J (J1))
Program Officer
Song, Min-Kyung H
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
University of Pittsburgh
Schools of Medicine
United States
Zip Code
Okada, Hideho; Butterfield, Lisa H; Hamilton, Ronald L et al. (2015) Induction of robust type-I CD8+ T-cell responses in WHO grade 2 low-grade glioma patients receiving peptide-based vaccines in combination with poly-ICLC. Clin Cancer Res 21:286-94
Guo, Z S; Bartlett, D L (2014) Oncolytic viruses as platform for multimodal cancer therapeutics: a promising land. Cancer Gene Ther 21:261-3
Ohkuri, Takayuki; Ghosh, Arundhati; Kosaka, Akemi et al. (2014) STING contributes to antiglioma immunity via triggering type I IFN signals in the tumor microenvironment. Cancer Immunol Res 2:1199-208
Kosaka, Akemi; Ohkuri, Takayuki; Okada, Hideho (2014) Combination of an agonistic anti-CD40 monoclonal antibody and the COX-2 inhibitor celecoxib induces anti-glioma effects by promotion of type-1 immunity in myeloid cells and T-cells. Cancer Immunol Immunother 63:847-57
Hamilton, Ronald; Krauze, Michal; Romkes, Marjorie et al. (2013) Pathologic and gene expression features of metastatic melanomas to the brain. Cancer 119:2737-46
Kohanbash, Gary; McKaveney, Kayla; Sakaki, Masashi et al. (2013) GM-CSF promotes the immunosuppressive activity of glioma-infiltrating myeloid cells through interleukin-4 receptor-*. Cancer Res 73:6413-23
Okada, Hideho; Scheurer, Michael E; Sarkar, Saumendra N et al. (2013) Integration of epidemiology, immunobiology, and translational research for brain tumors. Ann N Y Acad Sci 1284:17-23
Sampath, Padma; Li, Jun; Hou, Weizhou et al. (2013) Crosstalk between immune cell and oncolytic vaccinia therapy enhances tumor trafficking and antitumor effects. Mol Ther 21:620-8
Yeung, Jacky T; Hamilton, Ronald L; Ohnishi, Koji et al. (2013) LOH in the HLA class I region at 6p21 is associated with shorter survival in newly diagnosed adult glioblastoma. Clin Cancer Res 19:1816-26
Bartlett, David L; Liu, Zuqiang; Sathaiah, Magesh et al. (2013) Oncolytic viruses as therapeutic cancer vaccines. Mol Cancer 12:103

Showing the most recent 10 out of 37 publications